An antibody prodrug capable of being selectively activated in a central nervous system (CNS) by protease KLK6 includes an antibody for treating a disease or disorder in the CNS； a KLK6 cleavable peptide fused to an N-terminus of a heavy chain and/or a light chain of the antibody； and a blocker fused to an N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, inflammatory disease, autoimmune disease, infectious disease, or neuron degeneration disease.
